Vertex Pharmaceuticals Inc (VRTX) company profile
Close on Nov 12, 2026Market cap $137.53BP/E 31.6Yield –
About Vertex Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Vertex Pharmaceuticals Incorporated is a biotechnology company operating within the pharmaceuticals segment that focuses on discovering, developing, and commercializing innovative therapies. Its commercial portfolio and product pipeline feature treatments such as TRIKAFTA/KAFTRIO, ALYFTREK, CASGEVY, and JOURNAVX, alongside collaborative research and development programs. The company supplies its therapeutic products primarily to specialized wholesale distributors, retail pharmacy chains, and healthcare distributors, including McKesson Corporation, Accredo Health Group Inc., and LloydsPharmacy.
The enterprise maintains an international operating and commercial footprint across the United States, the United Kingdom, Europe, and other global regions. Vertex conducts administrative, research, and business functions through designated facilities including its principal executive offices and headquarters located in Boston, Massachusetts.
Summary of the business section of Vertex Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vertex Pharmaceuticals Inc
- Founded
- 1989
- Headquarters
- Boston, MA
- Address
- 50 Northern Avenue 02210
- Phone
- (617) 341-6393
- Website
- www.vrtx.com
- Employees
- 600,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Massachusetts
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- VRTX
- Exchange
- Nasdaq
- IPO date
- Jul 24, 1991
- Shares outstanding
- 253M, Jul 31, 2026
- Public float
- $113.40B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Aug 24, 2000
- SEC CIK
- 875320
- CUSIP
- 92532F100
- ISIN
- US92532F1003
- FIGI
- BBG000C1S2X2
- Share class FIGI
- BBG001S68LJ8
- LEI
- 54930015RAQRRZ5ZGJ91
- EIN
- 04-3039129
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Reshma Kewalramani | CEO & President, Director | 86,471 |
| Jeffrey M. Leiden | Executive Chairman, Director | 35,237 |
| Grunsven Jasper van | EVP, CP and NPPO | 8,682 |
| Kristen Ambrose | SVP & Chief Accounting Officer | 11,624 |
| Amit Sachdev | EVP Chief Patient & Ext Af Off | 74,031 |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 53,572 |
| Duncan McKechnie | EVP, Chief Commercial Officer | 11,001 |
| Joy Liu | EVP and Chief Legal Officer | 19,131 |
| Carmen Bozic | EVP and CMO | 15,337 |
| Mark E. Bunnage | EVP, Chief Scientific Officer | 7,284 |
| Charles F. Wagner Jr | EVP, CO & FO | 47,042 |
| Jonathan Biller | EVP and Chief Legal Officer | 13,659 |
| Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | 18,432 |
| David Altshuler | EVP, Chief Scientific Officer | 34,477 |
| Stuart A. Arbuckle | EVP, COO | 63,508 |
| Daniel J. Brennan | Director | 795 |
| Alan M. Garber | Director | 7,344 |
| Bruce I. Sachs | Director | 39,000 |
| Michel Lagarde | Director | 1,132 |
| Nancy Thornberry | Director | 2,109 |
| Diana McKenzie | Director | 3,381 |
| Lloyd Carney | Director | 6,315 |
| Sangeeta N. Bhatia | Director | 4,924 |
| Suketu Upadhyay | Director | 1,558 |
| Jennifer Schneider | Director | 2,190 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $21.14M | $38.22M | $7.73M | $192 | $125 |
| FY2024 | $21.54M | $43.61M | $8.09M | $170 | $93 |
| FY2023 | $20.59M | $44.20M | $7.38M | $172 | $94 |
| FY2022 | $15.86M | $29.53M | $8.98M | $122 | $90 |
| FY2021 | $15.20M | $18.34M | $7.19M | $93 | $100 |
| FY2020 | $16.47M | $31.32M | $6.70M | $108 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Reshma Kewalramani CEO and President | $1.60M | $15.00M | $4.12M | $423.35K | $21.14M | -2% |
| Charles F. Wagner, Jr. EVP & Chief Operating and Financial Officer | $974.81K | $5.25M | $1.97M | $51.18K | $8.24M | +3% |
| Carmen Bozic EVP & Chief Medical Officer | $835.00K | $4.38M | $1.38M | $57.54K | $6.65M | – |
| Amit Sachdev EVP & Chief Patient and External Affairs Officer | $700.00K | $4.90M | $1.16M | $21.30K | $6.78M | – |
| Nia Tatsis EVP & Chief Regulatory and Quality Officer | $750.00K | $4.90M | $1.28M | $42.24K | $6.97M | -5% |
| Stuart A. Arbuckle Former EVP & Chief Operating Officer | $521.49K | $9.34M | – | $132.93K | $10.00M | +7% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“and Europe, and more than 600,000 people globally.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 22, 2024 | Tender offer | Third-party tender offer for the company's shares |
| Oct 27, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 25, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 31, 2014 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 29, 2014 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 11, 2009 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 13, 2009 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 4, 2008 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 7, 2005 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 23, 2001 | Merger | Registration of securities for a merger or exchange offer (S-4) |
See a number that looks wrong?